Exosomes as nature's nano carriers: Promising drug delivery tools and targeted therapy for glioma.

Rashmi Rana, Shamjetsabam Nandibala Devi, Amit Kumar Bhardwaj, M H Yashavarddhan, Deepika Bohra, Nirmal Kumar Ganguly
{"title":"Exosomes as nature's nano carriers: Promising drug delivery tools and targeted therapy for glioma.","authors":"Rashmi Rana, Shamjetsabam Nandibala Devi, Amit Kumar Bhardwaj, M H Yashavarddhan, Deepika Bohra, Nirmal Kumar Ganguly","doi":"10.1016/j.biopha.2024.117754","DOIUrl":null,"url":null,"abstract":"<p><p>Exosomes, minute vesicles originating from diverse cell types, exhibit considerable potential as carriers for drug delivery in glioma therapy. These naturally occurring nanocarriers facilitate the transfer of proteins, RNAs, and lipids between cells, offering advantages such as biocompatibility, efficient cellular absorption, and the capability to traverse the blood-brain barrier (BBB). In the realm of cancer, particularly gliomas, exosomes play pivotal roles in modulating tumor growth, regulating immunity, and combating drug resistance. Moreover, exosomes serve as valuable biomarkers for diagnosing diseases and assessing prognosis. This review aims to elucidate the therapeutic and diagnostic promise of exosomes in glioma treatment, highlighting the innovative advances in exosome engineering that enable precise drug loading and targeting. By circumventing challenges associated with current glioma treatments, exosome-mediated drug delivery strategies can enhance the efficacy of chemotherapy drugs like temozolomide and overcome drug resistance mechanisms. This review underscores the multifaceted roles of exosomes in glioma pathogenesis and therapy, underscoring their potential as natural nanocarriers for targeted therapy and heralding a new era of hope for glioma treatment.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"182 ","pages":"117754"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.biopha.2024.117754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Exosomes, minute vesicles originating from diverse cell types, exhibit considerable potential as carriers for drug delivery in glioma therapy. These naturally occurring nanocarriers facilitate the transfer of proteins, RNAs, and lipids between cells, offering advantages such as biocompatibility, efficient cellular absorption, and the capability to traverse the blood-brain barrier (BBB). In the realm of cancer, particularly gliomas, exosomes play pivotal roles in modulating tumor growth, regulating immunity, and combating drug resistance. Moreover, exosomes serve as valuable biomarkers for diagnosing diseases and assessing prognosis. This review aims to elucidate the therapeutic and diagnostic promise of exosomes in glioma treatment, highlighting the innovative advances in exosome engineering that enable precise drug loading and targeting. By circumventing challenges associated with current glioma treatments, exosome-mediated drug delivery strategies can enhance the efficacy of chemotherapy drugs like temozolomide and overcome drug resistance mechanisms. This review underscores the multifaceted roles of exosomes in glioma pathogenesis and therapy, underscoring their potential as natural nanocarriers for targeted therapy and heralding a new era of hope for glioma treatment.

外泌体作为自然界的纳米载体:有前途的药物输送工具和胶质瘤的靶向治疗。
外泌体是源自不同细胞类型的微小囊泡,在胶质瘤治疗中作为药物递送载体表现出相当大的潜力。这些天然存在的纳米载体促进了蛋白质、rna和脂质在细胞之间的转移,具有生物相容性、有效的细胞吸收和穿越血脑屏障(BBB)的能力等优点。在癌症领域,特别是胶质瘤领域,外泌体在调节肿瘤生长、调节免疫和抵抗耐药性方面发挥着关键作用。此外,外泌体作为诊断疾病和评估预后的有价值的生物标志物。本文旨在阐明外泌体在胶质瘤治疗中的治疗和诊断前景,强调外泌体工程的创新进展,使药物精确装载和靶向。通过规避当前胶质瘤治疗相关的挑战,外泌体介导的药物递送策略可以提高替莫唑胺等化疗药物的疗效并克服耐药机制。这篇综述强调了外泌体在胶质瘤发病和治疗中的多方面作用,强调了它们作为靶向治疗的天然纳米载体的潜力,预示着胶质瘤治疗的新时代的希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信